Phase 2 Trial, Mosunetuzumab Plus Pirtobrutinib, Waldenstrom Macroglobulinemia

Summary

NIH ClinicalTrials.gov has registered a Phase 2 clinical trial (NCT07548450) to evaluate the safety and tolerability of mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory Waldenstrom Macroglobulinemia. The trial, designated MPOWER, involves two interventions and is classified as Phase 2. Healthcare providers and clinical investigators involved in hematologic oncology research may consider this trial relevant for patient referral or study participation.

About this source

ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.

What changed

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Mentioned entities

Related changes

Phenobarbital ICU Agitated Delirium Phase 3 Trial

Routine Apr 23, 2026 • ClinicalTrials.gov Studies • Healthcare & Life Sciences

Dimethyl Fumarate Phase 2 Trial for Type 1 Diabetes Beta-Cell Preservation

Routine Apr 23, 2026 • ClinicalTrials.gov Studies • Healthcare & Life Sciences

RAPID-CKD Phase 4 Trial, Simultaneous 4 Guideline-Directed CKD Therapies

Routine Apr 23, 2026 • ClinicalTrials.gov Studies • Healthcare & Life Sciences